<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942249</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00256</org_study_id>
    <nct_id>NCT04942249</nct_id>
  </id_info>
  <brief_title>Long COVID in Military Organisations</brief_title>
  <acronym>LoCoMo</acronym>
  <official_title>Long COVID in Military Organisations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Labor Speiz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Armed Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitatsspital Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, longitudinal cohort study designed to follow-up on 500 Swiss military&#xD;
      personnel who tested in 2020 for SARS-CoV-2 (regardless of whether positive or negative, but&#xD;
      with a known test result). Participants are invited to undergo an intensive test battery to&#xD;
      evaluate if they suffer COVID-19 sequelae. The testing will include evaluation of several&#xD;
      body systems (cardio-vascular, pulmonary, neurological, ophthalmological, psychological and&#xD;
      general) and male fertility in a voluntary subgroup. Immune markers and SARS-CoV-2&#xD;
      reinfection rates will also be evaluated. The study hypothesis is that SARS-CoV-2 infection&#xD;
      causes a multi-system disease with sequelae detectable in a significant proportion of army&#xD;
      recruits after infection with SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the COVID-19 pandemic, many members of the Swiss armed forces (SAF) contracted&#xD;
      SARS-CoV-2. Up to one fifth may suffer from long-term sequelae, or so-called &quot;Long COVID&quot;.&#xD;
      The &quot;LoCoMo&quot; study is a prospective, longitudinal cohort study designed to follow-up on 500&#xD;
      tested recruits who tested either positive or negative while serving in the SAF in early&#xD;
      2020.&#xD;
&#xD;
      The aim of this research project is to evaluate long-term sequelae that may have occurred in&#xD;
      members of the armed forces. By following up on those army recruits who tested positive and&#xD;
      who were either symptomatic or asymptomatic and comparing them with those who test negative;&#xD;
      symptoms and sequelae of the infection and impact on life quality can be tracked. The&#xD;
      acquired data will also provide insights into the duration of immunity (or lack thereof)&#xD;
      after symptomatic and asymptomatic infection and the kinetics of antibody decline in those&#xD;
      who test positive. Furthermore, the study allows to follow-up on those army recruits who have&#xD;
      confirmed positive tests for SARS-CoV-2 and to compare them to those who were negative. The&#xD;
      data collected with this extensive test battery allows for a follow-up on a wide range of&#xD;
      symptoms, estimated rates of re-infection as well as long- term sequelae after infection,&#xD;
      including impact on ophthalmological function, on life quality and activities and impact on&#xD;
      male fertility.&#xD;
&#xD;
      The results of the study can also be extrapolated to health-care workers and other young&#xD;
      adults who constitute the backbone of the workforce. Because the proposed test battery is&#xD;
      very broad and comprehensive it may also detect hitherto unknown, long-term sequelae, which&#xD;
      might provide insight in the pathophysiology and general understanding of consequences of&#xD;
      SARS-CoV-2 infection which is the basis to develop strategies to mitigate the sequelae. This&#xD;
      study will provide essential knowledge on the multi-organ impact of COVID-19 in young persons&#xD;
      in Switzerland.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to longitudinally follow-up on a cohort of 500 military who tested either positive or negative for SARS-CoV-2 in early 2020 for possible sequelae, one year post infection</measure>
    <time_frame>One year</time_frame>
    <description>The primary endpoint is the occurrence of SARS-CoV-2 infection sequelae in a longitudinally follow-up cohort of a total of 500 military who tested either positive or negative for SARS-CoV-2 in early 2020.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcomes from components of the test battery</measure>
    <time_frame>One year</time_frame>
    <description>The test battery will detect anticipated sequelae in the following categories: general systemic, pulmonary, cardiac, male fertility, psychological, ophthalmological.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <description>167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <description>167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No evidence of infection</arm_group_label>
    <description>167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_label>No evidence of infection</arm_group_label>
    <arm_group_label>Symptomatic</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva and blood.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The project population is Swiss army recruits who were tested for SARS-CoV-2 in 2020&#xD;
        (regardless of whether they tested positive or negative, but with a known test result). The&#xD;
        total number of participants is 500 stratified to 167 participants per infection status&#xD;
        (symptomatic, asymptomatic or no evidence of infection).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Army recruits and personnel who tested for SARS-CoV-2.&#xD;
&#xD;
          -  Completion of a consent form.&#xD;
&#xD;
          -  Willing to participate and to complete the testing day in Zürich.&#xD;
&#xD;
        Additional inclusion criteria solely for the voluntary spermiogram test:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  No known abnormality of the reproductive system (e.g. Klinefelter-Syndrome)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to provide consent. Unable to attend the testing day in Zurich.&#xD;
&#xD;
          -  A narrow-angle glaucoma or sensitivity to a component of the Tropicamide eye drops is&#xD;
             not an exclusion criterion, but the eye examination will be performed without&#xD;
             pharmacological mydriasis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Epidemiology, Biostatistics and Prevention Institute at the University of Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Azim D, Nasim S, Kumar S, Hussain A, Patel S. Neurological Consequences of 2019-nCoV Infection: A Comprehensive Literature Review. Cureus. 2020 Jun 24;12(6):e8790. doi: 10.7759/cureus.8790. Review.</citation>
    <PMID>32601577</PMID>
  </reference>
  <reference>
    <citation>Banerjee D, Viswanath B. Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. Asian J Psychiatr. 2020 Dec;54:102350. doi: 10.1016/j.ajp.2020.102350. Epub 2020 Aug 12. Review.</citation>
    <PMID>33271682</PMID>
  </reference>
  <reference>
    <citation>Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, Ellis H, Goodall D, Gough M, Lewis S, Norman J, Papadopoulou T, Roscoe D, Sherwood D, Turner P, Walker T, Mistlin A, Phillip R, Nicol AM, Bennett AN, Bahadur S. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020 Aug;54(16):949-959. doi: 10.1136/bjsports-2020-102596. Epub 2020 May 31.</citation>
    <PMID>32475821</PMID>
  </reference>
  <reference>
    <citation>Battaglini D, Brunetti I, Anania P, Fiaschi P, Zona G, Ball L, Giacobbe DR, Vena A, Bassetti M, Patroniti N, Schenone A, Pelosi P, Rocco PRM, Robba C. Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings. Front Neurol. 2020 Aug 12;11:845. doi: 10.3389/fneur.2020.00845. eCollection 2020. Review.</citation>
    <PMID>32903391</PMID>
  </reference>
  <reference>
    <citation>Bielecki M, Züst R, Siegrist D, Meyerhofer D, Crameri GAG, Stanga Z, Stettbacher A, Buehrer TW, Deuel JW. Social Distancing Alters the Clinical Course of COVID-19 in Young Adults: A Comparative Cohort Study. Clin Infect Dis. 2021 Feb 16;72(4):598-603. doi: 10.1093/cid/ciaa889.</citation>
    <PMID>32594121</PMID>
  </reference>
  <reference>
    <citation>Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.</citation>
    <PMID>32644129</PMID>
  </reference>
  <reference>
    <citation>Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, Qin Y, Xiao K, Zhang H, Sun X. Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol. 2020 Dec;98(8):e951-e959. doi: 10.1111/aos.14472. Epub 2020 May 18.</citation>
    <PMID>32421258</PMID>
  </reference>
  <reference>
    <citation>Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020 Nov 3;324(17):1723-1724. doi: 10.1001/jama.2020.19719.</citation>
    <PMID>33031513</PMID>
  </reference>
  <reference>
    <citation>Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, Toresdahl BG, Rodeo SA, Casey EK, Mendias CL. Musculoskeletal Consequences of COVID-19. J Bone Joint Surg Am. 2020 Jul 15;102(14):1197-1204. doi: 10.2106/JBJS.20.00847.</citation>
    <PMID>32675661</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Patricia Schlagenhauf</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

